PetIQ, Inc. (NASDAQ:PETQ – Get Rating) – Analysts at Jefferies Financial Group issued their Q3 2022 earnings per share (EPS) estimates for PetIQ in a note issued to investors on Wednesday, September 21st. Jefferies Financial Group analyst C. Grady expects that the company will post earnings per share of ($0.12) for the quarter. The consensus estimate for PetIQ's current full-year earnings is $0.86 per share. Jefferies Financial Group also issued estimates for PetIQ's Q4 2022 earnings at ($0.16) EPS, FY2022 earnings at $0.62 EPS, Q1 2023 earnings at $0.49 EPS, Q2 2023 earnings at $0.40 EPS, Q3 2023 earnings at ($0.02) EPS, Q4 2023 earnings at ($0.03) EPS and FY2023 earnings at $0.86 EPS.
Get PetIQ alerts:PetIQ (NASDAQ:PETQ – Get Rating) last posted its quarterly earnings results on Tuesday, August 9th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.18. PetIQ had a negative net margin of 1.53% and a positive return on equity of 9.27%. The firm had revenue of $252.01 million during the quarter, compared to the consensus estimate of $259.28 million.
Separately, Raymond James decreased their price target on shares of PetIQ from $29.00 to $21.00 in a research note on Wednesday, August 10th.PetIQ Stock Performance
PetIQ stock opened at $8.33 on Friday. The company has a 50 day moving average price of $13.17 and a 200-day moving average price of $17.11. The company has a debt-to-equity ratio of 1.69, a quick ratio of 1.54 and a current ratio of 2.88. PetIQ has a fifty-two week low of $8.18 and a fifty-two week high of $27.09. The company has a market capitalization of $244.99 million, a PE ratio of -17.00, a P/E/G ratio of 1.27 and a beta of 1.52.
Hedge Funds Weigh In On PetIQ
Several institutional investors and hedge funds have recently bought and sold shares of the company. Captrust Financial Advisors grew its holdings in shares of PetIQ by 1,149.6% during the second quarter. Captrust Financial Advisors now owns 1,562 shares of the company's stock valued at $26,000 after buying an additional 1,437 shares during the last quarter. Byrne Asset Management LLC purchased a new stake in shares of PetIQ during the fourth quarter valued at $28,000. Eagle Bay Advisors LLC grew its holdings in shares of PetIQ by 142.9% during the second quarter. Eagle Bay Advisors LLC now owns 1,683 shares of the company's stock valued at $28,000 after buying an additional 990 shares during the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of PetIQ by 158.7% during the second quarter. BNP Paribas Arbitrage SA now owns 6,227 shares of the company's stock valued at $105,000 after buying an additional 3,820 shares during the last quarter. Finally, Amalgamated Bank purchased a new stake in shares of PetIQ during the first quarter valued at $107,000.
About PetIQ
(Get Rating)
PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications.
Featured Articles
- Get a free copy of the StockNews.com research report on PetIQ (PETQ)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.